NUWELLIS INC (NUWE)

US67113Y6032 - Common Stock

1  -0.01 (-0.99%)

After market: 1.02 +0.02 (+2%)

Fundamental Rating

3

Overall NUWE gets a fundamental rating of 3 out of 10. We evaluated NUWE against 187 industry peers in the Health Care Equipment & Supplies industry. While NUWE seems to be doing ok healthwise, there are quite some concerns on its profitability. NUWE is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NUWE has reported negative net income.
NUWE had a negative operating cash flow in the past year.
NUWE had negative earnings in each of the past 5 years.
In the past 5 years NUWE always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -253.91%, NUWE is doing worse than 94.65% of the companies in the same industry.
Looking at the Return On Equity, with a value of -537.37%, NUWE is doing worse than 88.77% of the companies in the same industry.
Industry RankSector Rank
ROA -253.91%
ROE -537.37%
ROIC N/A
ROA(3y)-118.33%
ROA(5y)-169.36%
ROE(3y)-299.28%
ROE(5y)-428.46%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NUWE has a Gross Margin of 63.65%. This is in the better half of the industry: NUWE outperforms 65.24% of its industry peers.
NUWE's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NUWE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y16.14%

More info and screens

5

2. Health

2.1 Basic Checks

NUWE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NUWE has been reduced compared to 1 year ago.
NUWE has more shares outstanding than it did 5 years ago.
NUWE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

NUWE has an Altman-Z score of -65.27. This is a bad value and indicates that NUWE is not financially healthy and even has some risk of bankruptcy.
NUWE has a Altman-Z score of -65.27. This is amonst the worse of the industry: NUWE underperforms 94.65% of its industry peers.
There is no outstanding debt for NUWE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -65.27
ROIC/WACCN/A
WACC9.19%

2.3 Liquidity

A Current Ratio of 2.03 indicates that NUWE has no problem at all paying its short term obligations.
With a Current ratio value of 2.03, NUWE is not doing good in the industry: 66.31% of the companies in the same industry are doing better.
A Quick Ratio of 1.34 indicates that NUWE should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.34, NUWE is doing worse than 66.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.03
Quick Ratio 1.34

More info and screens

6

3. Growth

3.1 Past

NUWE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.67%, which is quite impressive.
NUWE shows a small growth in Revenue. In the last year, the Revenue has grown by 3.57%.
Measured over the past years, NUWE shows a quite strong growth in Revenue. The Revenue has been growing by 12.13% on average per year.
EPS 1Y (TTM)83.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.75%
Revenue 1Y (TTM)3.57%
Revenue growth 3Y6.01%
Revenue growth 5Y12.13%
Sales Q2Q%-1.87%

3.2 Future

The Earnings Per Share is expected to grow by 25.93% on average over the next years. This is a very strong growth
NUWE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.83% yearly.
EPS Next Y94.46%
EPS Next 2Y41.21%
EPS Next 3Y25.93%
EPS Next 5YN/A
Revenue Next Year1.52%
Revenue Next 2Y10.49%
Revenue Next 3Y16.63%
Revenue Next 5Y36.83%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NUWE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUWE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

NUWE's earnings are expected to grow with 25.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.21%
EPS Next 3Y25.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NUWE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUWELLIS INC

NASDAQ:NUWE (12/20/2024, 8:00:01 PM)

After market: 1.02 +0.02 (+2%)

1

-0.01 (-0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-11 2024-11-11/bmo
Earnings (Next)N/A N/A
Inst Owners1.08%
Inst Owner Change67.45%
Ins Owners0.01%
Ins Owner Change0%
Market Cap4.37M
Analysts80
Price Target16.32 (1532%)
Short Float %7.53%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)54.57%
Min EPS beat(2)-124.14%
Max EPS beat(2)233.27%
EPS beat(4)2
Avg EPS beat(4)35.9%
Min EPS beat(4)-124.14%
Max EPS beat(4)233.27%
EPS beat(8)5
Avg EPS beat(8)27.52%
EPS beat(12)8
Avg EPS beat(12)19.18%
EPS beat(16)10
Avg EPS beat(16)16.52%
Revenue beat(2)1
Avg Revenue beat(2)2.91%
Min Revenue beat(2)-1.58%
Max Revenue beat(2)7.39%
Revenue beat(4)1
Avg Revenue beat(4)-1.29%
Min Revenue beat(4)-9.02%
Max Revenue beat(4)7.39%
Revenue beat(8)3
Avg Revenue beat(8)-3.53%
Revenue beat(12)5
Avg Revenue beat(12)-4.6%
Revenue beat(16)6
Avg Revenue beat(16)-4.21%
PT rev (1m)0%
PT rev (3m)-5.88%
EPS NQ rev (1m)-616.67%
EPS NQ rev (3m)-616.67%
EPS NY rev (1m)7.28%
EPS NY rev (3m)7.28%
Revenue NQ rev (1m)-5.39%
Revenue NQ rev (3m)-5.39%
Revenue NY rev (1m)0.28%
Revenue NY rev (3m)0.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.49
P/FCF N/A
P/OCF N/A
P/B 1.37
P/tB 1.37
EV/EBITDA N/A
EPS(TTM)-92.71
EYN/A
EPS(NY)-2.65
Fwd EYN/A
FCF(TTM)-2.48
FCFYN/A
OCF(TTM)-2.48
OCFYN/A
SpS2.05
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -253.91%
ROE -537.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.65%
FCFM N/A
ROA(3y)-118.33%
ROA(5y)-169.36%
ROE(3y)-299.28%
ROE(5y)-428.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y16.14%
F-Score4
Asset Turnover1.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.47%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.03
Quick Ratio 1.34
Altman-Z -65.27
F-Score4
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)48.61%
Cap/Depr(5y)85.79%
Cap/Sales(3y)2.33%
Cap/Sales(5y)3.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.75%
EPS Next Y94.46%
EPS Next 2Y41.21%
EPS Next 3Y25.93%
EPS Next 5YN/A
Revenue 1Y (TTM)3.57%
Revenue growth 3Y6.01%
Revenue growth 5Y12.13%
Sales Q2Q%-1.87%
Revenue Next Year1.52%
Revenue Next 2Y10.49%
Revenue Next 3Y16.63%
Revenue Next 5Y36.83%
EBIT growth 1Y34.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.94%
OCF growth 3YN/A
OCF growth 5YN/A